Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found
Articles 1 records found  
1.
14 p, 4.9 MB Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs / Nogales, Vanesa (Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain) ; Reinhold, William C. (Genomics and Bioinformatics Group, Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD, USA) ; Varma, Sudhir (Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA) ; Martinez-Cardus, Anna (Institut de Recerca Biomèdica Bellvitge (IDIBELL)) ; Moutinho, Catia (Institut de Recerca Biomèdica Bellvitge (IDIBELL)) ; Moran, Sebastian (Institut de Recerca Biomèdica Bellvitge (IDIBELL)) ; Heyn, Holger (Institut de Recerca Biomèdica Bellvitge (IDIBELL)) ; Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Barnadas, Agusti (Institut d'Investigació Biomèdica Sant Pau) ; Pommier, Yves (Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA) ; Esteller, Manel (Institucio Catalana de Recerca i Estudis Avançats (ICREA)) ; Universitat Autònoma de Barcelona
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. [...]
2015 - 10.18632/oncotarget.6413
Oncotarget, Vol. 7 (november 2015) , p. 3084-3097  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.